The Life Raft Group is partnering with Dr. Neeta Somaiah of MD Anderson Cancer Center to host “Gaining Insight on the Phase 3 INSIGHT Clinical Trial” for the GIST community on April 11th, 2024 from 12-1:15 pm ET. During the webinar, Dr. Somaiah will present an overview of Deciphera Pharmaceutical’s Phase 3 INSIGHT Clinical Trial. This study tests the investigational use of ripretinib in a subset of patients living with GIST. Webinar participants will learn about the INSIGHT study, including eligibility, site locations, and study rationale. A Q & A session will follow the presentation.
Please email srothschild@liferaftgroup.org to submit a question ahead of the presentation.
Please note that this webinar is not a substitute for your physician’s guidance and care.
About Our Presenter
Neeta Somaiah, MD
MD Anderson Cancer Center
Dr. Neeta Somaiah received her medical degree from Maulana Azad Medical College in New Delhi, India and has trained at St. John’s Episcopal in New York, Drexel University Hospital and Fox Chase Cancer Center in Philadelphia, prior to joining MD Anderson Cancer Center.
Dr. Somaiah joined MD Anderson Cancer Center in 2012. She has thirteen years of sarcoma and clinical research experience. She is board certified in Medical Oncology. Her primary clinical and research focus is soft tissue sarcomas, specifically liposarcomas and GIST. She currently serves as the Principal Investigator of three investigator-initiated trials and nine cooperative group and industry-sponsored clinical trials at MD Anderson Cancer Center and has in depth knowledge with extensive experience in the design and execution of clinical trials. She also has multiple ongoing collaborations for translational research, both retrospective and prospective, that help improve the understanding of these rare group of diseases and explore the role of immunotherapy as a therapeutic avenue. Dr. Somaiah has been presented many honors for her expertise and contributions to science, including an Exceptional Women in Medicine award and is among the top 1% providers nationally.
Thank you to our Webinar Sponsor!
